• Coherus Oncology published “Tagmokitug CCR8+ Treg Depleter Interim Clinical Update,” reporting interim results in esophageal cancer.
• First-line tagmokitug with toripalimab and chemotherapy achieved a 75% confirmed response rate among eight evaluable patients.
• Second-line treatment at 700 mg showed median progression-free survival of 5.5 months; data remain immature.
• Grade 3 or higher adverse events related to tagmokitug affected 20% of first-line patients versus 23.5% in second-line treatment.
• Plans include expanding first-line enrollment to 30–40 patients, with parallel first- and second-line development targeting global pivotal trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.